Decision on optimal combinatorial Therapies in IMIDS using Systems Approaches

Project Overview

DoCTIS is an EU-funded translational project aimed at addressing the urgent need to discover effective therapeutic strategies for immune-mediated inflammatory diseases.


Biomedical research partners from five different European countries as well as from the United States of America are collaborating toward this.

Work Packages

The DoCTIS project is structured in nine different work packages, involving animal model, patient, systems biology and clinical evaluation stages.


DoCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches”. DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis. Through the generation of high volumes of data using of modern high-throughput technologies on samples from well-characterized IMID patients, and the use of advanced systems biology analytical approaches, we aim to identify therapeutic combinations that are much more efficacious and safer than current single-drug approaches.


Follow the most recent activity generated from the DoCTIS project.


See DoCTIS in the media and published work derived from the project.


Calendar of future and past events associated to the DoCTIS project.


If you are a patient suffering from an IMID, click here to know more on how the research at the DoCTIS project is working to help you.

Congratulations to #Doctis partner #IMIDomics on this massive achievement

The present symposium will provide the most recent advances in #combinationtherapy identification and application in human disease, with international experts in #translational research and medicine

IMIDomics is a partner of EU H2020 project “DoCTIS: Decision on Combinatorial Therapies in IMIDs” @DoctisEU, a multicentric project involving diverse basic, applied and clinical research aimed at improving treatment efficacy in Immune-Mediated Inflammatory Diseases (#IMIDs)

🔴#SavetheDate On October 7th we have organised a symposium event focused on “Combination therapies in common diseases: clinical and translational challenges”. Further information coming soon.

Mark your calendars!


#Combinationtherapy in #IBD – from traditional immunosuppressors towards the new paradigm of dual targeted therapy

Load More…